文献速递糖尿病

住院2型糖尿病患者中的闭环胰岛素输注:一项随机平行组试验

Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2016-11-09

这项单中心、开放标签、平行组随机对照试验纳入40例接受胰岛素治疗的2型糖尿病住院患者,比较闭环胰岛素输注与常规皮下胰岛素治疗。闭环组目标血糖范围内时间比例为59.8%,对照组为38.1%,差异21.8%(95%CI 10.4-33.1;p=0.0004)。两组均未发生严重低血糖或伴酮血症的高血糖。

要点

  • 闭环胰岛素输注组目标血糖范围内时间比例为59.8%,对照组为38.1%。
  • 两组间目标血糖范围内时间比例差异为21.8%(95%CI 10.4-33.1;p=0.0004)。
  • 两组均未发生严重低血糖或伴酮血症的高血糖。

核心结论

  • 在普通病房接受胰岛素治疗的2型糖尿病成人患者中,不进行餐时胰岛素大剂量注射的闭环胰岛素输注是有效且安全的。

研究设计与样本

  • 单中心、开放标签、平行组随机对照试验,纳入40例18岁及以上接受胰岛素治疗的2型糖尿病患者,按1:1随机分为闭环胰岛素输注组(20例)和常规皮下胰岛素治疗组(20例)。
  • 闭环胰岛素输注使用模型预测控制算法指导速效胰岛素类似物的皮下输注,不进行餐时胰岛素大剂量注射;对照组按当地临床指南进行常规皮下胰岛素治疗。
  • 主要结局为72小时研究期间血糖浓度在5.6-10.0 mmol/L目标范围内的时间比例,分析采用意向性治疗原则。

主要发现

  • 闭环组目标血糖范围内时间比例为59.8%(SD 18.7),对照组为38.1%(SD 16.7),差异为21.8%(95%CI 10.4-33.1;p=0.0004)。
  • 两组均未发生严重低血糖或伴酮血症的高血糖。
  • 研究期间发生1例与研究装置无关的不良事件(胃肠道出血)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed whether fully closed-loop insulin delivery (the so-called artificial pancreas) is safe and effective compared with standard subcutaneous insulin therapy in patients with type 2 diabetes in the general ward. METHODS: For this single-centre, open-label, parallel-group, randomised controlled trial, we enrolled patients aged 18 years or older with type 2 diabetes who were receiving insulin therapy. Patients were recruited from general wards at Addenbrooke's Hospital, Cambridge, UK. Participants were randomly assigned (1:1) by a computer-generated minimisation method to receive closed-loop insulin delivery (using a model-predictive control algorithm to direct subcutaneous delivery of rapid-acting insulin analogue without meal-time insulin boluses) or conventional subcutaneous insulin delivery according to local clinical guidelines. The primary outcome was time spent in the target glucose concentration range of 5·6-10·0 mmol/L during the 72 h study period. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01774565. FINDINGS: Between Feb 20, 2015, and March 24, 2016, we enrolled 40 participants, of whom 20 were randomly assigned to the closed-loop intervention group and 20 to the control group. The proportion of time spent in the target glucose range was 59·8% (SD 18·7) in the closed-loop group and 38·1% (16·7) in the control group (difference 21·8% [95% CI 10·4-33·1]; p=0·0004). No episodes of severe hypoglycaemia or hyperglycaemia with ketonaemia occurred in either group. One adverse event unrelated to study devices occurred during the study (gastrointestinal bleed). INTERPRETATION: Closed-loop insulin delivery without meal-time boluses is effective and safe in insulin-treated adults with type 2 diabetes in the general ward. FUNDING: Diabetes UK; European Foundation for the Study of Diabetes; JDRF; National Institute for Health Research Cambridge Biomedical Research Centre; Wellcome Trust.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Thabit H, Hartnell S, Allen JM, et al. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. 2016. PMID: 27836235. doi:10.1016/S2213-8587(16)30280-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。